Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The blockbuster weight loss drug semaglutide can cut the progression of diabetic kidney disease, according to its manufacturer Novo Nordisk, adding to growing evidence that the medication has ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved semaglutide (Ozempic) to reduce the risk of kidney disease worsening, kidney failure, and death due to ...

Semaglutide reduced the risk of kidney disease worsening ... “This approval for Ozempic allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects ...

Novo Nordisk has reported headline results from the FLOW trial, where its semaglutide demonstrated a 24% reduction in kidney disease progression and mortality. The parallel-group, superiority ...

Semaglutide reduced the risk of kidney ... us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious ...